Ray Patnaude – Page 12 – Safe Biologics

ASBM Presents to WHO, Urging International Harmonization of Biologic Nomenclature

October 28, 2019

On October 22nd, ASBM presented at the World Health Organization’s (WHO’s) 69th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. This was the thirteenth INN Consultation at which ASBM has presented. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. While the discussions in the Open Session […]

Fact Sheet: What Can Canada Learn from the European Biosimilar Experience?

October 28, 2019

The undisputed leader in biosimilars with more than 60 products approved and the largest biosimilar market in the world, Europe has achieved impressive biosimilar uptake rates. These can be as high as 91% for older products (before the approval of the first monoclonal antibody biosimilar in 2013) and up to 43% for newer products (approved […]

ASBM Presents at Biosimilar World Congress: Europe

October 20, 2019

On October 15th and 16th, ASBM participated in the Biosimilar World Congress: Europe 2019, part of the three-day Festival of Biologics held in Basel, Switzerland. ASBM was represented at the conference by Advisory Board Chair Philip Schneider and Steering Committee member Andrew Spiegel, executive director of the Global Colon Cancer Association. On the first day, Dr. Schneider […]

ASBM Releases Preliminary Findings from European Prescribers Survey at ESMO 2019

October 1, 2019

September 30, 2019 – Barcelona, Spain – The Alliance for Safe Biologic Medicines (ASBM) this week shared preliminary findings from a survey of 575 biologic prescribers in six Western European countries, covering several key policy issues including biosimilar substitution practices, adverse event reporting, and government tendering criteria. Since 2010, the group has routinely surveyed physicians […]

Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative

September 23, 2019

Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative VANCOUVER, BC – Wednesday, September 18, 2019. On September 5, 2019, the BC government announced phase two of its Biosimilars Initiative, informing patients prescribed the originator biologic drug, Remicade® (infliximab), to treat inflammatory bowel disease (Crohn’s disease and ulcerative colitis) that this medication […]

ASBM Releases Fact Sheet on British Columbia vs EU Substitution Policies

August 5, 2019

As BC attempts to increase biosimilar use by force-switching 23,000 patients, Europe enjoys high uptake rates while preserving patient and physician choice. On August 5th, ASBM released a fact sheet contrasting the biosimilar substitution policies of European countries (which generally have robust biosimilar markets) with the newly announced British Columbia policy. First fact sheet also addresses misconceptions […]

June-July 2019 Newsletter

August 1, 2019

newsletter | June-July 2019 issue 79 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]

ASBM Exhibits, Presents at DIA 2019 Annual Meeting

July 29, 2019

WHO INN Programme Lead Dr. Raffaella Balocco visits with Advisory Board Chair Philip Schneider (left) and Executive Director Michael Reilly (right) at ASBM’s booth. From June 24th to June 26th, ASBM exhibited at the DIA 2019 Global Annual Meeting in San Diego, CA. ASBM was represented by Executive Director Michael Reilly and Advisory Board Chair Philip Schneider, […]

ASBM Op-ed published in Vancouver Sun

June 24, 2019

Michael Reilly: Forcing patients to switch to biosimilars puts them in uncharted waters MICHAEL REILLY Updated: June 24, 2019 On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, effective Nov. 22, with serious, chronic conditions from their current biologic medicines to lower-cost “biosimilar” treatments. The roughly 23,000 patients […]

ASBM Exhibits at 2019 BIO Conference

June 8, 2019

From June 4th-6th, ASBM exhibited at the 2019 BIO International Convention held in Philadelphia, PA. Each year, the BIO International Convention attracts approximately 16,000 attendees from more than 5,000 companies and from 70 different countries. ASBM was represented at the booth by Andrew Spiegel, ASBM Steering Committee member and executive director of the Global Colon Cancer Association. At ASBM’s booth, attendees […]